Investigating the effects of MMS22L loss and PARP inhibitors in prostate cancer
Official title: MMS22L loss and PARP inhibition in prostate cancer
Funded at Brigham and Women's Hospital · NIH-11052649 · Data updated 2026-11-12
This study is exploring how to create personalized treatments for men with advanced prostate cancer by looking at their tumor's genes, especially those related to DNA repair, to see who might benefit most from a specific type of medication called PARP inhibitors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $409,463 |
| NIH project number | 5R01CA279410-03 |
| Project ID | NIH-11052649 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with metastatic castration-resistant prostate cancer, particularly those with BRCA1 or BRCA2 mutations.
✕Less likely to help
Patients with early-stage prostate cancer or those without specific genetic mutations related to DNA damage response may not benefit from this research.
What this research studies
This research focuses on metastatic castration-resistant prostate cancer (mCRPC), a challenging condition with limited treatment options. It aims to develop personalized therapies based on genomic alterations in tumors, particularly looking at how defects in DNA damage response genes like BRCA1 and BRCA2 affect treatment outcomes. By using PARP inhibitors, which target cancer cells that cannot repair their DNA effectively, the study seeks to identify which patients are most likely to benefit from these therapies. The approach involves analyzing genetic markers to tailor treatments to individual patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with advanced prostate cancer.
How similar studies have gone: Previous research has shown promising results with PARP inhibitors in similar patient populations, indicating a potential for success in this approach.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Jia, Li — Brigham and Women's Hospital
- Study coordinator: Jia, Li
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.